In a phase 3 study (NCT04028778), 315 patients with treatment-naïve, EGFR-mutated, advanced NSCLC were randomized (1:1) to receive anlotinib or placebo plus gefitinib once daily on days 1–14 per a 3-week cycle. This evidence concerns the gene EGFR and non-small cell lung carcinoma.